MARKET

CERO

CERO

CERo Therapeutics
OTCMQB
0.011
0.000
0.00%
Closed 14:04 09/14 EDT
OPEN
0.010
PREV CLOSE
0.011
HIGH
0.011
LOW
0.0095
VOLUME
237.57K
TURNOVER
2.41K
52 WEEK HIGH
5.72
52 WEEK LOW
0.0075
MARKET CAP
780.78K
P/E (TTM)
-0.0008
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CERO last week (0831-0904)?
Weekly Report · 09/07 09:59
CERo Therapeutics Holdings Secures New Consolidated Financing Facility
TipRanks · 08/31 21:21
Weekly Report: what happened at CERO last week (0824-0828)?
Weekly Report · 08/31 10:05
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
Barchart · 08/31 06:30
Weekly Report: what happened at CERO last week (0817-0821)?
Weekly Report · 08/24 10:05
Weekly Report: what happened at CERO last week (0810-0814)?
Weekly Report · 08/17 10:06
CERO THERAPEUTICS HOLDINGS, INC. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026
Press release · 08/15 07:45
Weekly Report: what happened at CERO last week (0803-0807)?
Weekly Report · 08/10 10:02
More
About CERO
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Webull offers CERo Therapeutics Holdings Inc stock information, including OTCMQB: CERO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERO stock methods without spending real money on the virtual paper trading platform.